A novel approach for the detection and genetic analysis of live melanoma circulating tumor cells

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Xu, Melody J ^a   Cooke, Mariana ^a   Steinmetz, David ^a   Karakousis, Giorgos ^b   Saxena, Deeksha ^a   Bartlett, Edmund ^b   Xu, Xiaowei ^b   Hahn, Stephen M ^a   Dorsey, Jay F ^a   Kao, Gary D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; MELAN A; TELOMERASE REVERSE TRANSCRIPTASE; B RAF KINASE; BRAF PROTEIN, HUMAN; TELOMERASE;

ADULT; ARTICLE; BRAF GENE; CELL ADHESION; CELL COUNT; CELL GROWTH; CELL SIZE; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME ACTIVITY; ENZYME ASSAY; FEMALE; GENE AMPLIFICATION; GENE MUTATION; GENETIC ANALYSIS; HOMOZYGOSITY; HUMAN; HUMAN CELL; MALE; MELANOMA; MELANOMA CELL; MUTATIONAL ANALYSIS; ONCOGENE; PILOT STUDY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; ADENOVIRIDAE; AGED; AREA UNDER THE CURVE; FLUORESCENT ANTIBODY TECHNIQUE; GENE VECTOR; GENETICS; METABOLISM; METASTASIS; MIDDLE AGED; MUTATION; PATHOLOGY; STATISTICAL MODEL; TUMOR CELL LINE; TUMOR EMBOLISM;

ADENOVIRIDAE; ADULT; AGED; AREA UNDER CURVE; CELL LINE, TUMOR; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENETIC VECTORS; HUMANS; LINEAR MODELS; MALE; MELANOMA; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; PILOT PROJECTS; PROTO-ONCOGENE PROTEINS B-RAF; ROC CURVE; TELOMERASE;

EID: 84926464644     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0123376     Document Type: Article

References (38)

1. U.S. Cancer Statistics Working Group. United States cancer statistics: 1999-2008 Incidence and mortality web-based report. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2013. Available: www.cdc.gov/uscs.
2. American Cancer Society. What are the survival rates for melanoma skin cancer by stage? Available: http://www.cancer.org/cancer/skincancer-melanoma/detailedguide/melanoma-skin-cancer-survival-rates. Accessed 2013 Jul 16.
3. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012; 366: 925-931. doi: 10.1056/NEJMoa1112824 PMID: 22397654
4. Stamell EF, Wolchok JD, Gnjatic S, Lee NY, Brownell I. The abscopal effect associated with a systemic anti-melanoma immune response. Int J Radiat Oncol Biol Phys. 2013; 85: 293-295. doi: 10.1016/j.ijrobp.2012.03.017 PMID: 22560555
5. Okwan-Duodu D, Pollack BP, Lawson D, Khan MK. Role of radiation therapy as immune activator in the era of modern immunotherapy for metastatic malignant melanoma. American Journal of Clinical Oncology. 2013. [Epub ahead of print] doi: 10.1097/COC.0b013e3182940dc3
6. Jarkowski A 3rd, Norris L, Trinh VA. Controversies in the management of advanced melanoma: "Gray" areas amid the "black and blue". Ann Pharmacother. 2014; 48(11):1456-68. doi: 10.1177/1060028014544165 PMID: 25056920
7. Paterlini-Brechot P, Benali NL. Circulating tumor cells (CTC) detection: Clinical impact and future directions. Cancer Lett. 2007; 253: 180-204. PMID: 17314005
8. Steen S, Nemunaitis J, Fisher T, Kuhn J. Circulating tumor cells in melanoma: A review of the literature and description of a novel technique. Proc (Bayl Univ Med Cent). 2008; 21: 127-132. PMID: 18382750
9. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004; 351: 781-791. PMID: 15317891
10. Pantel K, Brakenhoff RH, Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer. 2008; 8: 329-340. doi: 10.1038/nrc2375 PMID: 18404148
11. Rao C, Bui T, Connelly M, Doyle G, Karydis I, Middleton MR, et al. Circulating melanoma cells and survival in metastatic melanoma. Int J Oncol. 2011; 38: 755-760. doi: 10.3892/ijo.2011.896 PMID: 21206975
12. Khoja L, Lorigan P, Zhou C, Lancashire M, Booth J, Cummings J, et al. Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma. J Invest Dermatol. 2013; 133: 1582-1590. doi: 10.1038/jid.2012.468 PMID: 23223143
13. Karakousis G, Yang R, Xu X. Circulating melanoma cells as a predictive biomarker. J Invest Dermatol. 2013; 133: 1460-1462. doi: 10.1038/jid.2013.34 PMID: 23673501
14. Sakaizawa K, Goto Y, Kiniwa Y, Uchiyama A, Harada K, Shimada S, et al. Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level. Br J Cancer. 2012; 106: 939-946. doi: 10.1038/bjc.2012.12 PMID: 22281663
15. Luo X, Mitra D, Sullivan RJ, Wittner BS, Kimura AM, Pan S, et al. Isolation and molecular characterization of circulating melanoma cells. Cell reports. 2014; 7: 645-653. doi: 10.1016/j.celrep.2014.03.039 PMID: 24746818
16. Mocellin S, Hoon D, Ambrosi A, Nitti D, Rossi CR. The prognostic value of circulating tumor cells in patients with melanoma: A systematic review and meta-analysis. Clin Cancer Res. 2006; 12: 4605-4613. PMID: 16899608
17. Nicholl MB, Elashoff D, Takeuchi H, Morton DL, Hoon DS. Molecular upstaging based on paraffin-embedded sentinel lymph nodes: Ten-year follow-up confirms prognostic utility in melanoma patients. Ann Surg. 2011; 253: 116-122. doi: 10.1097/SLA.0b013e3181fca894 PMID: 21135695
18. Hoshimoto S, Faries MB, Morton DL, Shingai T, Kuo C, Wang HJ, et al. Assessment of prognostic circulating tumor cells in a phase III trial of adjuvant immunotherapy after complete resection of stage IV melanoma. Ann Surg. 2012; 255: 357-362. doi: 10.1097/SLA.0b013e3182380f56 PMID: 22202581
19. Hoshimoto S, Shingai T, Morton DL, Kuo C, Faries MB, Chong K, et al. Association between circulating tumor cells and prognosis in patients with stage III melanoma with sentinel lymph node metastasis in a phase III international multicenter trial. J Clin Oncol. 2012; 30: 3819-3826. doi: 10.1200/JCO.2011.40.0887 PMID: 23008288
20. Scoggins CR, Ross MI, Reintgen DS, Noyes RD, Goydos JS, Beitsch PD, et al. Prospective multi-institutional study of reverse transcriptase polymerase chain reaction for molecular staging of melanoma. J Clin Oncol. 2006; 24: 2849-2857. PMID: 16782924
21. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer. 1997; 33: 787-791. PMID: 9282118
22. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, et al. Specific association of human telomerase activity with immortal cells and cancer. Science. 1994; 266: 2011-2015. PMID: 7605428
23. Kojima T, Hashimoto Y, Watanabe Y, Kagawa S, Uno F, Kuroda S, et al. A simple biological imaging system for detecting viable human circulating tumor cells. J Clin Invest. 2009; 119: 3172-3181. doi: 10.1172/JCI38609 PMID: 19729837
24. Maida Y, Kyo S, Sakaguchi J, Mizumoto Y, Hashimoto M, Mori N, et al. Diagnostic potential and limitation of imaging cancer cells in cytological samples using telomerase-specific replicative adenovirus. Int J Oncol. 2009; 34: 1549-1556. PMID: 19424572
25. Ju M, Kao GD, Steinmetz D, Chandrasekaran S, Keefe SM, Guzzo TJ, et al. Application of a telomerase-based circulating tumor cell (CTC) assay in bladder cancer patients receiving postoperative radiation therapy: A case study. Cancer Biol Ther. 2014; 15: 683-687. doi: 10.4161/cbt.28412 PMID: 24618718
26. Macarthur KM, Kao GD, Chandrasekaran S, Alonso-Basanta M, Chapman C, Lustig RA, et al. Detection of brain tumor cells in the peripheral blood by a telomerase promoter-based assay. Cancer Res. 2014; 74: 2152-2159. doi: 10.1158/0008-5472.CAN-13-0813 PMID: 24525740
27. Dorsey JF, Kao GD, MacArthur KM, Ju M, Steinmetz D, Wileyto EP, et al. Tracking viable circulating tumor cells (CTCs) in the peripheral blood of non-small cell lung cancer patients undergoing definitive radiation therapy: Pilot study results. Cancer. 2015; 121: 139-149. doi: 10.1002/cncr.28975 PMID: 25241991
28. Kudo LC, Vi N, Ma Z, Fields T, Avliyakulov NK, Haykinson MJ, et al. Novel cell and tissue acquisition system (CTAS): Microdissection of live and frozen brain tissues. PLoS One. 2012; 7: e41564. doi: 10.1371/journal.pone.0041564 PMID: 22855692
29. Zong C, Lu S, Chapman AR, Xie XS. Genome-wide detection of single-nucleotide and copy-number variations of a single human cell. Science. 2012; 338: 1622-1626. doi: 10.1126/science.1229164 PMID: 23258894
30. Lin J, Goto Y, Murata H, Sakaizawa K, Uchiyama A, Saida T, et al. Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression. Br J Cancer. 2011; 104: 464-468. doi: 10.1038/sj.bjc.6606072 PMID: 21224857
31. Kang SY, Ahn S, Lee S, Jeong JY, Sung J, Oh YL, et al. Shifted termination assay (STA) fragment analysis to detect BRAF V600 mutations in papillary thyroid carcinomas. Diagn Pathol. 2013; 8: 121. doi: 10.1186/1746-1596-8-121 PMID: 23883275
32. Cleves MA, Rock L. From the help desk: Comparing areas under receiver operating characteristic curves from two or more probit or logit models. The Stata Journal. 2002; 2: 301-313.
33. Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol. 2011; 29: 1239-1246. doi: 10.1200/JCO.2010.32.4327 PMID: 21343559
34. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364: 2507-2516. doi: 10.1056/NEJMoa1103782 PMID: 21639808
35. Chiu CG, Nakamura Y, Chong KK, Huang SK, Kawas NP, Triche T, et al. Genome-wide characterization of circulating tumor cells identifies novel prognostic genomic alterations in systemic melanoma metastasis. Clin Chem. 2014; 60: 873-885. doi: 10.1373/clinchem.2013.213611 PMID: 24718909
36. Heaphy CM, Subhawong AP, Hong SM, Goggins MG, Montgomery EA, Gabrielson E, et al. Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol. 2011; 179: 1608-1615. doi: 10.1016/j.ajpath.2011.06.018 PMID: 21888887
37. Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, et al. Discovery of a selective inhibitor of oncogenic B-raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A. 2008; 105: 3041-3046. doi: 10.1073/pnas.0711741105 PMID: 18287029
38. Yu X, Ambrosini G, Roszik J, Eterovic AK, Stempke-Hale K, Seftor EA, et al. Genetic analysis of the 'uveal melanoma' C918 cell line reveals atypical BRAF and common KRAS mutations and single tandem repeat profile identical to the cutaneous melanoma C8161 cell line. Pigment Cell Melanoma Res. 2014.